EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants

Shichang Miao, Pirow Bekker, Danielle Armas, Mary Lor, Yanyan Han, Kenneth Webster, Ashit Trivedi

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Shichang Miao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Amgen, Inc., Thousand Oaks, CA, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C9, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inhibitors, Drug Interactions. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Avacopan, a complement 5a receptor (C5aR) antagonist approved for treating severe active antineutrophil cytoplasmic autoantibody (ANCA)‐associated vasculitis, was evaluated in 2 clinical drug‐drug interaction studies. The studies assessed the impact of avacopan on the pharmacokinetics (PK) of CYP3A4 substrates midazolam and simvastatin and CYP2C9 substrate celecoxib, and the influence of CYP3A4 inhibitor itraconazole and inducer rifampin on the PKs of avacopan. The results indicated that twice‐daily oral administration of 30 mg of avacopan increased the area under the curve (AUC) of midazolam by 1.81‐fold and celecoxib by 1.15‐fold when administered without food, and twice‐daily oral administration of 30 or 60 mg of avacopan increased the AUC of simvastatin by approximately 2.6‐3.5‐fold and the AUC of the active metabolite β‐hydroxy‐simvastatin acid by approximately 1.4‐1.7‐fold when co‐administered with food. Furthermore, the AUC of avacopan increased by approximately 2.19‐fold when co‐administered with itraconazole and decreased by approximately 13.5‐fold when co‐administered with rifampin. These findings provide critical insights into the potential drug‐drug interactions involving avacopan, which could have significant implications for patient care and treatment planning. (NCT06207682)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C9Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDrug InteractionsHealthy VolunteersItraconazoleMidazolamRifampinSimvastatinAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveFood-Drug Interactions

Stichwörter der Autor:innen

CYP2C9CYP3A4avacopaninteractionpharmacokinetics

Substanzen

Cytochrome P-450 CYP2C9Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsItraconazoleMidazolamRifampinSimvastatin

Autor:innen und Institutionen

  • Amgen, Inc., Thousand Oaks, CA, USA.
  • Celerion, Inc., Tempe, AZ, USA.

Zitieren

APA

Miao, S., Bekker, P., Armas, D., Lor, M., Han, Y., Webster, K., & Trivedi, A. (2024). Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1389

Vancouver

Miao S, Bekker P, Armas D, Lor M, Han Y, Webster K, et al. Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1389

BibTeX
@article{Miao2024,
  author = {Miao, Shichang and Bekker, Pirow and Armas, Danielle and Lor, Mary and Han, Yanyan and Webster, Kenneth and Trivedi, Ashit},
  title = {Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1389}
}
Kostenlos starten →